MultiplexDX at ESMO 2026 in Berlin
We are proud to be a part of the ESMO BREAST CANCER Annual Congress 2026, May 06.-08., in Berlin, one of the world’s most influential oncology meetings organized by the European Society for Medical Oncology. Bringing together leading oncologists, translational researchers, pathologists, and innovators from across the globe, ESMO continues to shape the future of precision oncology and cancer care.
For MultiplexDX, ESMO 2026 marks another important milestone in our international journey. As an official conference partner, we are honored to showcase our latest research, scientific vision, and molecular diagnostic innovations directly at our exhibition booth, where we are experiencing tremendous interest and inspiring discussions with experts from the global oncology community.
Our team is excited to present the clinical potential of Multiplex8+, engage in meaningful scientific exchange, and strengthen collaborations that help advance more personalized treatment strategies for cancer patients worldwide. Moments like these remind us how far Slovak biotechnology and translational science can reach when driven by passion, perseverance, and purpose.
We are grateful to everyone who visited our booth and shared in the enthusiasm for the future of precision medicine.
About MultiplexDX
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter
